Chargement en cours...

Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?

Lung cancer accounts for the majority of cancer-related deaths worldwide. At present, platinum-based therapy represents the standard of care in fit stage II and IIIA non-small cell lung cancer (NSCLC) patients following surgical resection. In advanced disease, personalized chemotherapy and targeted...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Transl Lung Cancer Res
Auteurs principaux: Massuti, Bartomeu, Sanchez, Jose Miguel, Hernando-Trancho, Florentino, Karachaliou, Niki, Rosell, Rafael
Format: Artigo
Langue:Inglês
Publié: Pioneer Bioscience Publishing Company 2013
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367596/
https://ncbi.nlm.nih.gov/pubmed/25806234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2013.03.06
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!